학술논문
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Document Type
Article
Author
Dandona, Paresh; Mathieu, Chantal; Phillip, Moshe; Hansen, Lars; Griffen, Steven C; Tschöpe, Diethelm; Thorén, Fredrik; Xu, John; Langkilde, Anna Maria; Proietto, Joseph; Stranks, Stephen; Chen, Roger; O'Neal, David; Pape, Alexia; Forbes, Mark; Morbey, Claire; Luger, Anton; Hanusch, Ursula; Schnack, Christoph; Fliesser-Goerzer, Evelyn; Hoelzl, Bertram; Ebenbichler, Christoph; Prager, Rudolf; Van Gaal, Luc; Vercammen, Chris; Scheen, Andre; Mathieu, Chantal; Duyck, Francis; Nobels, Frank; Ruige, Johannes; Aggarwal, Naresh; Woo, Vincent; St-Pierre, Bruno; Dumas, Richard; Hramiak, Irene; Elliott, Thomas; Krarup Hansen, Troels; Henriksen, Jan Erik; Gram, Jeppe; Lihn, Aina; Bruun, Jens; Saltevo, Juha; Taurio, Jyrki; Strand, Jorma; Valle, Timo; Nieminen, Sakari; Pietilainen, Kirsi; Guerci, Bruno; Hadjadj, Samy; Cariou, Bertrand; Verges, Bruno; Borot, Sophie; Penfornis, Alfred; Schaum, Thomas; Tschoepe, Diethelm; Marck, Cornelia; Horacek, Thomas; Rose, Ludger; Klausmann, Gerhard; Luedemann, Joerg; Appelt, Steffi; Aigner, Ulrich; Goebel, Rolf; Behnke, Thomas; Ziegler, Anette-Gabriele; Peterfai, Eva; Kerenyi, Zsuzsanna; Oroszlan, Tamas; Kiss, Gyula G.; Konyves, Laszlo; Piros, Gyorgyi; Phillip, Moshe; Mosenzon, Ofri; Shehadeh, Naim; Adawi, Faiad; Wainstein, Julio; Dotta, Francesco; Piatti, Piermarco; Genovese, Stefano; Consoli, Agostino; Di Bartolo, Paolo; Mannucci, Edoardo; Giordano, Carla; Lapolla, Annunziata; Aguilar, Carlos; Esteban, Alberto; Ruiz, Bazzoni; Ramirez, Guillermo Mondragon; Pelayo Orozco, Emilia; Alejandro, Carlos; de Alba, Stobschinski; Medina Pech, Carlos; Garza Ruiz, Jose; Sauque Reyna, Leobardo; Llamas Esperon, Guillermo; Nevarez Ruiz, Luis Alejandro; Vidrio Velazquez, Maricela; Flores Lozano, Fernando; Gonzalez Gonzalez, Jose Gerardo; Garcia-Hernandez, Pedro Alberto; Araujo-Silva, Roberto; Villeda - Espinosa, Efrain; Mistodie, Cristina; Popescu, Daniela; Constantin, Ciprian; Nicolau, Alina; Popa, Bogdan; Timar, Romulus; Serafinceanu, Cristian; Pintilei, Ella; Soto, Alfonso; Gimenez, Margarita; Merino-Torres, Juan Francisco; Morales, Cristobal; Mezquita, Pedro; Jendle, Johan; Tengmark, Bengt-Olov; Eriksson, Jan; Londahl, Magnus; Eliasson, Bjorn; Gunstone, Anthony; Heller, Simon; Darzy, Ken; Mansell, Peter; Davies, Melanie; Reed, Rory; Browne, Duncan; Courtney, Hamish; Turner, Wayne; Blagden, Mark; McCrimmon, Rory; Bergenstal, Richard; Lane, Wendy; Lucas, Kathryn; White, Alexander; Bao, Shichun; White, Judith; Jantzi, Curtis; Rasouli, Neda; Ervin, William; Lewy-Alterbaum, Lorena; Handelsman, Yehuda; Miranda-Palma, Bresta; Cleland, Alan; Fink, Raymond; Rodbard, Helena; Nakhle, Samer; Greenberg, Craig; Schorr, Alan; Bays, Harold; Simmons, Debra; Klein, Eric; Kane, Laurie; Fishman, Norman; Ipp, Eli; Garg, Satish; Bhargava, Anuj; Singh, Michelle Zaniewski; Rosenstock, Julio; Thrasher, James; Warren, Mark; Young, Laura; Aroda, Vanita; Pettus, Jeremy; Liljenquist, David; Busch, Robert; Dandona, Paresh; Wise, Jonathan; Kayne, David; Biggs, William
Source
The Lancet Diabetes & Endocrinology; November 2017, Vol. 5 Issue: 11 p864-876, 13p
Subject
Language
ISSN
22138587; 22138595
Abstract
Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes.